Further Strengthens Management Team of Industry Veterans to Support Commercialization of Potential New Antibiotic for Community-Acquired Bacterial Pneumonia DUBLIN, Ireland and KING OF PRUSSIA, Pa. , July 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical
DUBLIN, Ireland, June 26, 2017 – Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the
DUBLIN, Ireland , June 26, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (" Nabriva Therapeutics ") today announced that it has successfully concluded its previously announced tender offer related to the exchange of common shares (" Nabriva AG Common Shares ") of Nabriva Therapeutics plc ("
VIENNA, Austria and KING OF PRUSSIA, Pa. , June 05, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
Four abstracts demonstrate potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa. , June 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical
DUBLIN, Ireland , May 23, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (" Nabriva Ireland ") today commenced the previously announced tender offer related to the exchange of American depositary shares (" Nabriva AG ADSs ") and common shares (" Nabriva AG Common Shares ") of Nabriva
- Expects top-line data from LEAP 1 CABP Phase 3 trial in third quarter 2017 and from LEAP 2 CABP Phase 3 trial in first quarter 2018 Vienna, Austria / King of Prussia, PA, May 12, 2017 – Nabriva Therapeutics AG (NASDAQ: NBRV), a clinical stage biopharmaceutical company engaged in the research and
VIENNA, Austria and KING OF PRUSSIA, Pa. , April 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
VIENNA, Austria , April 17, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV) (" Nabriva AG ") announced that its supervisory board and management board approved the relocation of the holding company of Nabriva AG and its subsidiaries (" Nabriva Group ") from Austria to Ireland (the "
Nine abstracts support potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa. , April 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company
